Syncona Limited




Investment Holding Companies

Real-time Estimate Cboe Europe 07:06:21 2024-07-25 am EDT 5-day change 1st Jan Change
124.50 GBX -0.72% Intraday chart for Syncona Limited -0.95% +0.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Thor Energy drilling starts; Deltic accepts licence AN
Syncona Invests Additional $42.5 Million in Beacon Therapeutics MT
Syncona's portfolio Beacon Therapeutics raises USD170 million AN
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors CI
Syncona Chair & CEO Hollowood buys GBP100,000 in shares AN
Syncona Invests in Two Oncology Companies MT
Syncona swings to annual profit despite challenging market conditions AN
Transcript : Syncona Limited, 2024 Earnings Call, Jun 20, 2024
Syncona Posts Swings to Profit for FY24; Total Investment Income Rises MT
Syncona Adds Ionctura And Yellowstone Biosciences To Its Portfolio RE
Tranche Update on Syncona Limited's Equity Buyback Plan announced on September 29, 2023. CI
Syncona Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Syncona’s Freeline, SwanBio Combine to Form Spur Therapeutics MT
Syncona to invest GBP40 million into newly created Spur Therapeutics AN
Syncona notes Autolus's first quarter loss widens amid higher costs AN
Syncona's Freeline gets positive results for Gaucher disease AN
Jefferies cuts AJ Bell; Deutsche likes ConvaTec AN
Syncona agrees to sell stake in investee company for GBP7.4 million AN
Syncona to Sell Stake in Portfolio Company to Century Therapeutics MT
Syncona notes investee Achilles's annual loss narrows AN
Syncona portfolio company Autolus posts widened loss for 2023 AN
Syncona’s Takeover of Freeline Therapeutics Becomes Effective MT
Freeline shareholders approve Syncona acquisition AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona MT
Syncona portfolio strengthens in third quarter thanks to Autolus AN
Chart Syncona Limited
More charts
Logo Syncona Limited
Syncona Limited is a Guernsey-based closed-ended investment company. The Company’s investment objective is to achieve superior long-term capital appreciation from its investments. It seeks to achieve returns over the long term. It focuses on creating, building and scaling companies around science to create a diversified portfolio of 20-25 global healthcare businesses, across development stage and therapeutic areas. It focuses on developing treatments for patients by working in close partnership with academic founders and management teams. The Company makes its life science investments through Syncona Holdings Limited, a subsidiary of the Company. It maintains its capital pool through Syncona Investments LP Incorporated (the Partnership) in which the Company is the sole limited partner. The general partner of the Partnership is Syncona GP Limited (the General Partner), a wholly owned subsidiary of the Company. Syncona Investment Management Limited is its alternative investment manager.
More about the company
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BACT Stock
  4. News Syncona Limited
  5. Syncona’s Takeover of Freeline Therapeutics Becomes Effective